Biograil

The BIONDD platform enables oral administration of biologics currently requiring injections, using a capsule designed for efficient delivery with comparable exposure to injections.

CEO Karsten Lindhardt will present BIONDD technology at 4:30 pm under the title *‘Oral Delivery of Biologics with Bioavailability Similar to […]’*.

Klara Lindhardt, a student assistant at Biograil, presented her project on barriers to oral treatment of autoimmune diseases with adalimumab at the company in March 2024.

Biograil ApS secured €3 million in seed funding (expandable to €5 million), led by High-Tech Gründerfonds and including Megatrend Invest and Swiss Investment Group.

Biograil ApS added Sanner Ventures to its investor syndicate, led by High-Tech Gründerfonds and including Megatrend Invest.

Press Release: Biograil and CSL Sign Collaboration Agreement for development of certain CSL compounds using Biograil’s proprietary BIONDD technology.

Biograil is hiring an analytical scientist to develop and support its BIONDD oral delivery platform for peptides and biologics.

Chairman of the Board, Consulting CFO & Founder

Ester Caffarel-Salvador Director, Strategic Innovation, Rare Diseases, at Chiesi Inc., USA, Co-inventor of SOMA and LUMI

Verve Ventures, a Swiss-based venture capital firm, invests in deep-tech startups from the seed stage, supporting over 150 companies and facilitating exits through its network.

Biograil was established in 2019 and is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD technology to unlock the potential of transforming markets of injectable pharmaceutical products into convenient oral capsules.

Biograil’s Roskilde office contact details include phone (+45 3074 1129) and email (info@biograil.com).